Open an Account
search icon
3
NOTIFICATIONS
Best Algo trading app in India
Bigul

Q4FY22 Quarterly Result Announced for Sequent Scientific Ltd.

 Pharmaceuticals firm Sequent Scientific declares Q4FY22 result: Q4 FY22 Revenues at Rs 3,837 Million, FY22 Revenues at Rs 14,128 Million Q4 FY22 Revenues at Rs 3.83 Bn+; +11.7% cc API: Q4 strong performance at Rs 1.27 Bn, +11% cc Formulations at Rs 2.56 Bn ,+12.0% cc Latam, India & EMs drive strong growth India business crosses Rs 1 Bn sales milestone Q4 revenues of Rs 2.56 Bn,+12 % YoY cc growth Met expectations of double-digits growth (cc) for full year, enabled by a diversified market reach India business achieves key milestone, crosses landmark of Rs 1 Bn revenues for the year Europe weakness owing to supply chain pressures and slowdown in demand Surprises in currency volatility impact Turkey growth, uncertainty likely to continue in near future Result PDF
26-05-2022
Bigul

Annual report for Sequent Scientific Ltd. for FY-2022
26-05-2022
Bigul

SEQUENT SCIENTIFIC LTD. - 512529 - Outcome Of Board Meeting Held On May 25, 2022 Along With Audited Standalone & Consolidated Financial Results And Press Release For The Quarter And Year Ended March 31, 2022

 Pursuant to Regulation 30 (read with Part A of Schedule III) and Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors at its Meeting held today, inter-alia, considered and approved the Audited Standalone and Consolidated Financial Results for the quarter and year ended March 31, 2022. In this regard, kindly find enclosed the following Audited Consolidated Financial Results along with Independent Auditor's Review Report issued by the Statutory Auditors of the Company for the quarter and year ended March 31, 2022. 2. Audited Standalone Financial Results along with Independent Auditor's Review Report issued by the Statutory Auditors of the Company for the quarter and year ended March 31, 2022. 3. A copy of Press Release and Investors Presentation on Audited Standalone and Consolidated Financial Results for the quarter and year ended March 31, 2022
25-05-2022
Bigul

SEQUENT SCIENTIFIC LTD. - 512529 - Board Meeting Outcome for Outcome Of Board Meeting Held On May 25, 2022 Along With Audited Standalone & Consolidated Financial Results And Press Release For The Quarter And Year Ended March 31, 2022

 Pursuant to Regulation 30 (read with Part A of Schedule III) and Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors at its Meeting held today, inter-alia, considered and approved the Audited Standalone and Consolidated Financial Results for the quarter and year ended March 31, 2022. In this regard, kindly find enclosed the following: 1. Audited Consolidated Financial Results along with Independent Auditor's Review Report issued by the Statutory Auditors of the Company for the quarter and year ended March 31, 2022. 2. Audited Standalone Financial Results along with Independent Auditor's Review Report issued by the Statutory Auditors of the Company for the quarter and year ended March 31, 2022. 3. A copy of Press Release and Investors Presentation on Audited Standalone and Consolidated Financial Results for the quarter and year ended March 31, 2022.
25-05-2022
Bigul

SEQUENT SCIENTIFIC LTD. - 512529 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, kindly note that the Company has, as a part of its investors engagement activities, scheduled a conference call with the Analysts / Investors on Thursday, May 26, 2022, to discuss its Q4FY22 financial results. The Conference call details are enclosed. Event : Post Results Q4FY22 Conference Call Date & Time : Thursday, May 26, 2022 at 9:00 A.M. Phone Numbers: +91 22 6280 1263 +91 22 7115 8213
18-05-2022
Bigul

SEQUENT SCIENTIFIC LTD. - 512529 - Board Meeting Intimation for Consideration And Approval Of The Audited Standalone And Consolidated Financial Results Of The Company For The Quarter And Year Ended March 31, 2022.

 SEQUENT SCIENTIFIC LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/05/2022 ,inter alia, to consider and approve Pursuant to Regulation 29(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Meeting of the Board of Directors of SeQuent Scientific Limited ('the Company') is scheduled to be held on Wednesday, May 25, 2022 to consider and approve the Audited Standalone and Consolidated Financial Results of the Company for the quarter and year ended March 31, 2022. Further, in continuation to our intimation dated March 31, 2022, and pursuant to Company''s Code of Conduct to Regulate, Monitor and Report Trading by Designated Persons and their Immediate Relatives, the trading window for dealing in the securities of the Company is closed from April 01, 2022 till 48 hours after the declaration of Audited Financial Results of the Company for the quarter and year ended March 31, 2022. Kindly take the above on records.
18-05-2022
Bigul

SEQUENT SCIENTIFIC LTD. - 512529 - Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2

 Format of the Annual Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1 Name of Company SEQUENT SCIENTIFIC LTD. 2 CIN NO. L99999MH1985PLC036685 3 Report filed for FY 2021-2022 Details of the Current block (all figures in Rs crore): 4 2 - year block period (Specify financial years)* 2020-21, 2021-22 5 Incremental borrowing done in FY (T)(a) 0.00 6 Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a) 0.00 7 Actual borrowing done through debt securities in FY (T)(c) 0.00 8 Shortfall in the borrowing through debt securities, if any, for FY (T - 1) carried forward to FY (T) (d) 0 8Quantum of (d), which has been met from (c)(e)* 0 9 Shortfall, if any, in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)}(f) = (b) - [(c) - (e)]{ If the calculated value is zero or negative, write 'nil'}* 0 Details of penalty to be paid, if any, in respect to previous block (all figures in Rs crore): 2 - year Block period (Specify financial years)NA Amount of fine to be paid for the block, if applicable Fine = 0.2% of {(d) - (e)}#0.00 Name of the Company Secretary :-Krunal ShahDesignation :-Company Secretary and Compliance officer Name of the Chief Financial Officer :- Tushar Mistry Designation : -Chief Financial Officer Date: 14/05/2022
14-05-2022
Bigul

SEQUENT SCIENTIFIC LTD. - 512529 - Intimation Of Fire Incident In Wholly Owned Subsidiary'S Unit At Ramky Pharma City SEZ JNPC, Visakhapatnam Under Reg. 30 Of SEBI LODR, Reg. 2015

 We wish to inform you that there was an incident of fire at our wholly owned subsidiary Alivira Animal Health Limited's (Alivira) API facility in Visakhapatnam at around 7:30 pm on Saturday, May 7, 2022. The fire was brought under control soon. There were no casualties or injuries to anyone on site. While manufacturing activities have been affected temporarily, the initial assessment indicates that there might not be any material financial impact on account of this incident. The Company has appropriate insurance in place for the unit. The Company has also informed all concerned statutory authorities about the fire incident. Kindly take the same on your record.
09-05-2022
Bigul

SEQUENT SCIENTIFIC LTD. - 512529 - Format of Initial Disclosure to be made by an entity identified as a Large Corporate

 Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompaySEQUENT SCIENTIFIC LTD. 2CINL99999MH1985PLC036685 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 19.50 4Highest Credit Rating during the previous FY A+ 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)INDIA RATINGS AND RESEARCH PVT. LTD. 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Krunal Shah Designation: Company Secretary & Compliance Officer EmailId: [email protected] Name of the Chief Financial Officer: Tushar Mistry Designation: Chief Financial Officer EmailId: [email protected] Date: 26/04/2022 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.
26-04-2022
Bigul

SEQUENT SCIENTIFIC LTD. - 512529 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

 Dear Sir/ Madam, We wish to inform you that the Board of Directors of the Company vide a resolution passed by circulation on April 25, 2022, has approved issue and allotment of 10,62,500 Equity Shares of Rs. 2/- each fully paid to the Employees at an exercise price of Rs. 86/- per equity share on exercise of the options granted to them under SeQuent ESOP Plan 2020. The said Equity shares shall rank pari passu, in all respects with the existing equity shares of the Company. Consequent to the allotment of the aforesaid equity shares, the issued and the paid-up equity share capital of the Company will increase from Rs. 49,67,41,990 consisting of 24,83,70,995 Equity Shares of Rs. 2/- each to Rs. 49,88,66,990 consisting of 24,94,33,495 Equity Shares of Rs. 2/- each. Kindly take the same on your record.
26-04-2022
Next Page
Close

Let's Open Free Demat Account